Schering Corporation

Merck Sharp + Dohme Corp.

Patrick J Curran

M Arshad Siddiqui

Lianyun Zhao

Gerald Wayne Shipps, Jr

David Benjamin Belanger

Panduranga Adulla P Reddy

Blake Hamann

Timothy J Guzi

Yongqi Deng

Viyyoor Moopil Girijavallabhan

Michael P Dwyer

Kamil Paruch

Alan B Cooper

Umar Faruk Mansoor

Rumin Zhang

Kristin E Rosner

William T Windsor

Tong Wang

David Parry

Charles W McNemar

Praveen K Tadikonda

Todd W Mayhood

Emma M Lees

Vincent Stewart Madison

Janeta Popovici-Muller

Huw M Nash

Alan W Hruza

Thierry Olivier Fischmann

Matthew H Daniels

Andrew J McRiner

Zhaoyang Meng

Chaoyang Dai

Jagdish A Desai

Jose S Duca

Mehul F Patel

James J-s Wang

Liping Yang

Hugh Y Zhu

Gerald W Shipps

Shuyi Tang

Yang Nan

Duan Liu

Panduranga Adulla Reddy

Amit K Mandal

Angie R Angeles

D Allen Annis

Lalanthi Dilrukshi Vitharana

Janet Popovici-Muller

David A Parry

Andrew Mcriner

Matthew Hersh Daniels

Charles Wayne Mcnemar

The present invention provides Pyrazolopyrimidine Compounds of Formula (I): wherein L, T, Z, U, V, W, R, R, R, R, and m are as defined herein, and pharmaceutically acceptable salts of such Pyrazolopyrimidine Compounds. The Pyrazolopyrimidine Compounds are useful in the treatment of cancer and other diseases or disorders wherein mTOR is deregulated.

Pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors

Disclosed are compounds of the formula (I) wherein X is N or CH, and Y is N or CR. Also disclosed are methods of treating JNK and ERK mediated diseases using the compounds of formula 1.0. 

Substituted pyridines that are JNK inhibitors

In its many embodiments, the present invention provides a novel class of imidazo[1,2-a]pyrazine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions. An illustrative compound of the invention is shown below: 

Imidazopyrazines as cyclin dependent kinase inhibitors

In its many embodiments, the present invention provides a class of pyrazolo [1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases (CDKs), methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions. An illustrative compound of the invention is shown below: 

Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors

Quinoline-based inhibitors of cyclin dependent kinase 2, compositions including the inhibitors, and methods of using the inhibitors and inhibitor compositions are described. The inhibitors and compositions including them are useful for treating disease or disease symptoms. The invention also provides for methods of making CDK-2 inhibitor compounds, methods of inhibiting CDK-2, and methods for treating disease or disease symptoms.

High affinity quinoline-based kinase ligands

In its many embodiments, the present invention provides a novel class of imidazopyrazine compounds as inhibitors of protein and/or Aurora kinases, methods of preparing such compounds, pharmaceutical compositions including one or more such compounds, methods of preparing pharmaceutical formulations including one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the protein or Aurora kinases using such compounds or pharmaceutical compositions. An illustrative compound of the invention is shown below: 

Imidazopyrazines as protein kinase inhibitors

Inhibitors of cyclin dependent kinase 2, compositions including the inhibitors, and methods of using the inhibitors and inhibitor compositions are described. The inhibitors and compositions including them are useful for treating disease or disease symptoms. The invention also provides for methods of making CDK-2 inhibitor compounds, methods of inhibiting CDK-2, and methods for treating disease or disease symptoms.

High affinity thiophene-based and furan-based kinase ligands

The present invention provides compounds of formula I wherein X, Y, R-Rare as defined herein. Compositions containing these compounds, and methods for inhibiting HCV RNA-dependent RNA polymerase and treating hepatitis C and related disorders using these compounds and compositions are also provided. 

Substituted 5-carboxyamide pyrazoles and [1,2,4]triazoles as antiviral agents

The invention relates to the inhibition of hepatitis C virus (HCV) replication. In particular, embodiments of the invention provide compounds and methods for inhibiting HCV RNA-dependent RNA polymerase enzymatic activity. The invention also provides compositions and methods for the prophylaxis and treatment of HCV infection.

Pyrazolo[1,5a]pyrimidine compounds as antiviral agents

The present invention provides compounds of formula I wherein X and R&#x2013;Rare as defined herein. Compositions containing these compounds, and methods for inhibiting HCV RNA-dependent RNA polymerase and treating hepatitis C and related disorders using these compounds and compositions are also provided 

Substituted 5-oxo pyrazoles and [1,2,4]triazoles as antiviral agents

Growing community of inventors

Winthrop, MA, United States of America

Patrick J Curran